- Home
- FLYY vs ACTU Comparison
FLYY vs ACTU Comparison
Compare FLYY & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYY
- ACTU
- Stock Information
- Founded
- FLYY 2025
- ACTU 2015
- Country
- FLYY United States
- ACTU United States
- Employees
- FLYY N/A
- ACTU N/A
- Industry
- FLYY
- ACTU
- Sector
- FLYY
- ACTU
- Exchange
- FLYY NYSE
- ACTU NYSE
- Market Cap
- FLYY 119.2M
- ACTU 135.0M
- IPO Year
- FLYY N/A
- ACTU 2024
- Fundamental
- Price
- FLYY $4.85
- ACTU $6.15
- Analyst Decision
- FLYY
- ACTU Strong Buy
- Analyst Count
- FLYY 0
- ACTU 1
- Target Price
- FLYY N/A
- ACTU $20.00
- AVG Volume (30 Days)
- FLYY 351.1K
- ACTU 151.6K
- Earning Date
- FLYY 01-01-0001
- ACTU 05-15-2025
- Dividend Yield
- FLYY N/A
- ACTU N/A
- EPS Growth
- FLYY N/A
- ACTU N/A
- EPS
- FLYY N/A
- ACTU N/A
- Revenue
- FLYY $4,660,283,000.00
- ACTU N/A
- Revenue This Year
- FLYY N/A
- ACTU N/A
- Revenue Next Year
- FLYY N/A
- ACTU N/A
- P/E Ratio
- FLYY N/A
- ACTU N/A
- Revenue Growth
- FLYY N/A
- ACTU N/A
- 52 Week Low
- FLYY $4.68
- ACTU $5.50
- 52 Week High
- FLYY $13.00
- ACTU $11.99
- Technical
- Relative Strength Index (RSI)
- FLYY N/A
- ACTU N/A
- Support Level
- FLYY N/A
- ACTU N/A
- Resistance Level
- FLYY N/A
- ACTU N/A
- Average True Range (ATR)
- FLYY 0.00
- ACTU 0.00
- MACD
- FLYY 0.00
- ACTU 0.00
- Stochastic Oscillator
- FLYY 0.00
- ACTU 0.00
About FLYY SPIRIT AVIATION HOLDINGS INC
Spirit Aviation Holdings Inc is committed to safely delivering the best value in the sky by offering an enhanced travel experience with flexible, affordable options. Spirit serves destinations throughout the United States, Latin America and the Caribbean with its all-Airbus Fit Fleet, one of the youngest and most fuel-efficient fleets in the U.S. Discover elevated travel options with exceptional value.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.